Cervical Cancer

Cervical cancer is a malignancy of the cervix, most commonly squamous cell carcinoma (SCC), arising from persistent infection with high-risk human papillomavirus (HPV), particularly types 16 and 18. It represents the third most common cancer and fourth leading cause of cancer death in women worldwide, with approximately 14,000 new cases and 4,000 deaths annually in the United States. The epidemiology has shifted dramatically with implementation of cervical screening programs (Pap smear) and more recently HPV vaccination, creating a bimodal age distribution with peaks in the 40s and 60s. Cervical cancer remains clinically significant due to its preventability through screening and vaccination, making it a cornerstone topic for USMLE Step 2 CK, with board questions frequently testing understanding of prevention, early detection via cytology, and staging-based management.

The primary pathophysiologic driver is persistent infection with high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), which integrate into the host genome and disrupt normal cell cycle regulation. The viral E6 oncoprotein binds to and degrades p53 tumor suppressor protein through ubiquitin-mediated proteolysis, eliminating the critical "guardian of the genome" that normally triggers apoptosis or cell cycle arrest in response to DNA damage. Simultaneously, the E7 oncoprotein inactivates the retinoblastoma protein (Rb), preventing its normal function of sequestering E2F transcription factors and maintaining G1/S checkpoint control. This dual disruption of p53 and Rb pathways allows infected cervical epithelial cells to bypass multiple checkpoints, accumulate additional mutations, and progress toward malignancy over years to decades.

Normal cervical epithelium undergoes a well-characterized precancerous progression: HPV infection initially causes cytologic abnormalities classified as cervical intraepithelial neoplasia (CIN), graded I-III based on the proportion of epithelial thickness involved by immature dysplastic cells. CIN I (low-grade squamous intraepithelial lesion, LSIL) involves primarily the basal third and frequently regresses spontaneously due to host immune clearance; however, persistent infection with high-risk HPV drives progression to CIN II-III (high-grade squamous intraepithelial lesions, HSIL), where dysplasia involves >50% of epithelial thickness. CIN III represents carcinoma in situ and has significant risk of progression to invasive cancer if untreated. This progression typically occurs over 10-15 years, providing a critical window for screening and intervention, though some HPV 16/18 infections may progress more rapidly in immunocompromised patients.

As CIN lesions progress, additional mutations accumulate in genes controlling cell adhesion, differentiation, and apoptosis. Loss of E-cadherin, altered β-catenin signaling, and activation of PI3K/Akt and MAPK/ERK pathways promote epithelial-mesenchymal transition (EMT), allowing dysplastic cells to breach the basement membrane and invade the underlying stroma. Squamous cell carcinoma accounts for approximately 80% of cervical cancers and arises from the ectocervical squamous epithelium at the squamocolumnar junction—the region of greatest metaplasia and HPV susceptibility. Adenocarcinoma (10-15% of cases) arises from endocervical columnar epithelium and is particularly associated with HPV 18; these tumors are often diagnosed at more advanced stages because they are located proximally and escape detection by cervical cytology sampling. Neuroendocrine tumors and other rare histologies account for <5% of cervical malignancies.

High-risk HPV-infected cells produce viral proteins that downregulate MHC Class I expression, reducing antigen presentation and evading CD8+ T cell recognition. The HPV-infected cervical microenvironment is infiltrated by regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) that suppress anti-HPV immune responses through IL-10 and TGF-β production. Additionally, persistent HPV infection causes chronic inflammation with elevated levels of IL-6, TNF-α, and IL-8, which paradoxically promote neoplastic progression through NF-κB pathway activation, angiogenesis, and genomic instability. Host factors including impaired cell-mediated immunity (HPV+ individuals with CD4 counts <200 progress to invasive cancer at 5-year rates of 30-50%), smoking (which increases oxidative stress and impairs immune clearance), and estrogen-responsive elements on the HPV genome all contribute to progression.

Persistent infection with high-risk HPV types, particularly HPV 16 and 18, is the necessary prerequisite for virtually all cervical cancers (attributable fraction >99%). Sexual transmission occurs through microabrasions during intercourse; the majority of sexually active individuals acquire HPV at some point, though 90% spontaneously clear infection within 1-2 years. Persistent infection (lasting >12-24 months) is the critical risk factor distinguishing those who will develop precancerous lesions. HPV 16 accounts for ~50% and HPV 18 for ~20% of all cervical cancers globally; the remaining cases are caused by other high-risk types. The relationship between HPV and cervical cancer is so strong that HPV testing has become the primary screening modality in many developed nations.

Severely immunocompromised individuals, particularly those with CD4+ T cell counts <200 cells/μL from untreated HIV infection, have dramatically accelerated progression from CIN to invasive cancer, with annual progression rates of 5-10% compared to <1% in immunocompetent women. Solid organ transplant recipients on chronic immunosuppression and those with primary immunodeficiencies also demonstrate increased cervical cancer incidence. This relationship validates the pathophysiologic importance of cell-mediated immunity in controlling HPV; immune reconstitution with antiretroviral therapy in HIV+ women reduces cancer progression risk substantially.

Smoking increases cervical cancer risk 2-4 fold through multiple mechanisms: carcinogenic components (polycyclic aromatic hydrocarbons, nitrosamines) directly damage cervical epithelial DNA; smoking impairs local and systemic T cell responses to HPV; and smoking increases oxidative stress generating reactive oxygen species that promote genomic instability. The risk escalates with pack-years and duration of smoking, and is independent of HPV status, suggesting synergistic carcinogenic effects.

Long-term oral contraceptive use (≥5 years) confers a relative risk of 1.9-3.2 for cervical cancer, likely reflecting both prolonged epithelial exposure to HPV-infected endocervical cells (ectopy) and immunosuppressive effects of estrogen and progestin. This risk persists for years after discontinuation but decreases with time. The absolute risk remains low in the setting of adequate screening.

Multiparity (≥3-5 pregnancies) increases cervical cancer risk, possibly through increased cervical trauma, inflammation, and epithelial remodeling that facilitates HPV infection and persistence. Early age at first intercourse (<16-18 years) increases both HPV acquisition risk and progression to cancer, reflecting exposure during a biologically critical window of cervical development and immune maturation.

Maternal exposure to diethylstilbestrol (DES) in utero (now of historical interest) increased risk of cervical adenocarcinoma. Sexually transmitted infections including Chlamydia trachomatis and Neisseria gonorrhoeae increase cervical cancer risk through chronic inflammation. High dietary intake of folate and carotenoids are protective. Male partners with penile cancer history confer increased risk through exposure to high-risk HPV types.

Vaginal bleeding or bloody vaginal discharge is the most common presenting symptom, occurring in 60-80% of patients with invasive cervical cancer. The bleeding may be spontaneous, postcoital (bleeding after intercourse due to friable ulcerated tumor surface), or postmenopausal in older women. Physiologically, as the tumor grows through the epithelium and invades into the rich capillary bed of the cervical stroma and myometrium, neoplastic vessels are inherently fragile and prone to rupture with minimal trauma, producing intermittent bleeding and blood-stained mucoid discharge. The character of bleeding often prompts gynecologic evaluation that leads to diagnosis.

A profuse, foul-smelling, watery or blood-tinged vaginal discharge results from tumor necrosis and secondary bacterial superinfection of the friable tumor mass. This symptom may be the initial complaint and reflects the advanced stage of disease, as it develops as the tumor enlarges and ulcerates through the epithelium.

Pelvic pain, pelvic pressure, or dyspareunia (painful intercourse) develops as the tumor invades beyond the cervix into paracervical tissues, parametrial stroma, and pelvic sidewall structures. The pain is often described as constant and may radiate to the lower back, flanks, or lower extremities as the tumor involves pelvic nerves and sidewall musculature. In advanced disease with pelvic sidewall involvement or metastatic disease, severe pelvic pain may predominate.

Patients with advanced-stage disease may present with constitutional symptoms including unintentional weight loss, fatigue, and anorexia from the metabolic demands of advanced malignancy. Urinary symptoms such as dysuria, urinary frequency, urgency, or gross hematuria develop when the tumor invades the bladder. Rectal symptoms including tenesmus (painful defecation sensation), constipation, and bloody stools occur with rectal invasion. Lower extremity lymphedema develops from lymphatic obstruction by metastatic inguinal and pelvic lymph nodes. Neurologic symptoms including radicular pain in lower extremities result from invasion of pelvic nerves and sacral plexus.

On speculum examination, early cancers may be inapparent or manifest as an area of dysplasia or erosion on the cervix. More advanced lesions typically present as a friable, ulcerated, exophytic mass protruding from the cervix with spontaneous or contact bleeding, or as an endophytic infiltrative lesion causing cervical enlargement, firmness, and distortion of normal architecture. Foul-smelling purulent drainage or blood may be visible. Bimanual palpation may reveal parametrial induration or nodularity extending into paracervical tissues, lateral vaginal fornices, and pelvic sidewall—findings indicating stage IB2 or higher disease with extrauterine extension. Supraclavicular lymph node examination may reveal hard, fixed, matted lymph nodes suggesting metastatic disease.

Adenocarcinoma presents later (often stage IB2-IIB) because it arises from the endocervical canal where sampling is more difficult; patients may complain of watery vaginal discharge rather than bleeding. Neuroendocrine tumors (small cell carcinoma) are aggressive and often stage III-IV at diagnosis. Adenosquamous carcinomas have poorer prognosis than pure squamous cancers at equivalent stages.

Liquid-based cytology (LBC) remains the gold standard screening tool, with sensitivity of 60-95% for CIN II/III and specificity >95% depending on sample quality. Cytologic results are reported using the Bethesda System: normal/benign, atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), atypical glandular cells (AGC), and malignancy. HPV testing (polymerase chain reaction [PCR], hybrid capture, or genotyping) has become the primary screening modality in many developed countries; HPV reflex testing (performing HPV testing on ASC-US cases) improves specificity while maintaining sensitivity. HPV 16/18 genotyping provides prognostic information, as these types carry higher cancer risk than other high-risk types.

Visual inspection with acetic acid (VIA) or Lugol's iodine is used in resource-limited settings as a low-cost screening alternative. When cytology or HPV testing is abnormal, or when a visible lesion is present, colposcopy is performed: the cervix is magnified 10-20 times, and application of acetic acid (3-5%) causes acetowhitening of abnormal epithelium due to increased nuclear density and protein concentration. The colposcopist evaluates for mosaic vascular patterns, punctuation (fine dots), and coarse surface irregularities, which correlate with CIN grade. Lugol's iodine staining (Schiller test) causes normal glycogen-rich epithelium to stain brown; abnormal epithelium (lacking glycogen) remains unstained and appears yellow ("Schiller-positive"), helping identify biopsy sites.

Cervical tissue biopsy obtained during colposcopy is essential for diagnosis of invasive cancer. Histologic examination by light microscopy establishes:

HPV in situ hybridization or immunohistochemistry for p16 (surrogate for HPV infection) may aid diagnosis.

Staging of cervical cancer utilizes the FIGO (International Federation of Gynecology and Obstetrics) 2009 staging system, which is clinically based (no surgical staging except as treatment):

Imaging studies are not used for initial staging per FIGO but are essential for treatment planning:

Benign etiologies of vaginal bleeding must be excluded: cervicitis, cervical polyps, or cervical trauma. Endometrial cancer (in postmenopausal women with bleeding), uterine fibroids, endometrial polyps, and hormonal breakthrough bleeding should be considered. Vaginal leiomyomas can mimic cervical masses. Always obtain tissue confirmation before initiating cancer treatment.

**Early-Stage Disease (IA1-IB